Prevalence and factors of polypharmacy among disease-free survivors of adults after allogeneic hematopoietic cell transplantation
Leuk Lymphoma
.
2024 Apr;65(4):516-520.
doi: 10.1080/10428194.2023.2298698.
Epub 2023 Dec 27.
Authors
Eita Miyashita
1
,
Nozomi Sugihara
1
,
Miho Tanaka
1
,
Hiromi Iwasaki
1
,
Maki Monna-Oiwa
2
,
Masamichi Isobe
2
,
Seiko Kato
2
,
Satoshi Takahashi
2
,
Yasuhito Nannya
2
,
Yukari Tsuru
1
,
Takaaki Konuma
2
Affiliations
1
Department of Nursing, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
2
Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
PMID:
38149869
DOI:
10.1080/10428194.2023.2298698
No abstract available
MeSH terms
Adult
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Polypharmacy*
Prevalence
Survivors
Transplantation, Homologous